Fangsheng Pharmaceutical (603998.SH): Indobufen Tablets Obtain "Drug Registration Certificate"

Zhtng Cijng APP Xn, Fngshng Zhyo (603998.SH) Fb Gnggo, Jnr, Gngs Shudo Guji Yopn Jind Gunl J (jinchng "Guji Yojianj") Hkn Qinf de "Yopn Zhc Zhngsh," Gngs Ynf de Yndo Bfn Pin Y Hud Yopn Pzhn Wnho, Bng K Jnxng Shngchn. Yndo Bfn Sh Y Zhng Y Yndo Ln J Dngsun Ynshng Wling, Wi Y Zhng Xuxio Pnj de Yzh J. Zhtng Finance APP News, Fangsheng Pharmaceutical (603998.SH) issued an announcement. The company recently received the "Drug Registration Certificate" approved and issued by the National Medical Products Administration (referred to as the "National Drug Administration"). The company's research and development of Indobufen tablets has obtained a drug approval number and can now be produced. Indobufen is a derivative of indoleacetic acid, and is an inhibitor of platelet aggregation.